CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM051567
035-os BibID:PMID:10769717
Első szerző:Kiss István (Pécs)
Cím:Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes / István Kiss, János Sándor, Gábor Pajkos, Barna Bogner, Géza Hegedűs, István Ember
Dátum:2000
Megjegyzések:Chemical carcinogens generally require metabolic activation in order to be able to bind to DNA and contribute to cancer causation. Most of the human metabolizing enzymes are genetically polymorphic, and these polymorphisms may affect the enzyme activity or inducibility. In our present study we investigated the connection between genetic polymorphism of cytochrome P450 1A1, 2E1 (phase I enzymes) and glutathione-S-transferase M1 (a phase II enzyme) and colorectal cancer occurrence in a Hungarian population. The CYP 2E1 c2 allele proved to be in significant association with colorectal cancer (OR: 1.91, 95% CI: 1.05-3.52), the CYP 1A1 Val allele was also overrepresented among colon cancer patients (OR: 1.57, 95% CI: 0.90-2.74), and the frequency of GSTM1 homozygous 0 genotype showed only minor difference (OR: 1.19, 95% CI: 0.75-1.35). Combined analysis of the polymorphisms showed that individuals carrying all the three "high-risk" alleles have a strikingly increased risk for sporadic colorectal cancer (OR: 4.62, 95% CI: 1.23-25.68).
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
metabolizing enzymes
CYP 1Al
CYP 2E1
GSTM l
genetic polymorphisrn
cancer susceptibility
Megjelenés:Anticancer Research. - 20 : 1B (2000), p. 519-522. -
További szerzők:Sándor János (1966-) (orvos-epidemiológus) Pajkos Gábor Bogner Barna Hegedűs Géza Ember István
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM051588
035-os BibID:PMID:15736440
Első szerző:Kiss István (Pécs)
Cím:Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer / István Kiss, Árpád Németh, Barna Bogner, Gábor Pajkos, Zsuzsa Orsós, János Sándor, András Csejtei, Zsolt Faluhelyi, Imre Rodler, István Ember
Dátum:2004
Megjegyzések:Glutathione-S-transferases (GSTs) and N-acetyltransferases (NATs) are involved in the metabolism of a wide range of carcinogenic chemicals. Allelic polymorphism of these enzymes is associated with variations in enzyme activity, hence it may affect the concentration of activated carcinogenic chemicals in the body. Previous studies suggest a possible cancer risk-modifying effect of these allelic polymorphisms, but the results are still controversial. We evaluated the effect of GSTM1, GSTT1, GSTP1, NAT1 and NAT2 enzymes on individual susceptibility to colorectal cancer, with particular attention to possible interactions between the studied genotypes. MATERIALS AND METHODS: Five hundred colorectal cancer patients and 500 matched cancer-free controls were included in the study. The allelic polymorphisms of GSTM1, GSTT1 and GSTP1, NAT1 and NAT2 enzymes were determined by PCR-based methods, from peripheral blood leukocytes, and allelic distributions were compared between colorectal cancer patients and controls. RESULTS: The GSTM1 0 allele (OR: 1.48, 95% CI: 1.15-1.92) and rapid acetylator genotypes of NAT2 (OR: 1.52, 95% CI: 1.17-1.98) were associated with an elevated risk No statistically significant correlation between NAT1, GSTT1, GSTP1 genotypes and colorectal cancer was found. Remarkably increased risk was associated with the GSTM1 0 allele--NAT2 rapid acetylator genotype combination (OR: 2.39, 95% CI: 1.75-3.26) and with the GSTM1 0 allele--NAT2 and NAT1 rapid acetylator triple combination (OR: 3.28, 95% CI: 2.06-5.23). Carrying 4 or 5 putative "high-risk" alleles substantially increased the risk of colorectal cancer (OR: 3.69, 95% CI: 2.33-5.86). CONCLUSION: The genotype of certain metabolizing enzymes affects the risk for colorectal cancer. This effect is particularly important when certain allelic combinations are studied. In the near future, individual level risk assessment may be reached by further increasing the number of studied polymorphisms, combining them with traditional epidemiological risk factors.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
colorectal cancer
metabolizing enzvmes
cancer susceptibility
N-acetyltransferase
glutathione-S-transferase
Megjelenés:Anticancer Research. - 24 : 6 (2004), p. 3965-3970. -
További szerzők:Németh Árpád Bogner Barna Pajkos Gábor Orsós Zsuzsa Sándor János (1966-) (orvos-epidemiológus) Csejtei András Faluhelyi Zsolt Rodler Imre Ember István
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM105441
Első szerző:Nádasi Edit
Cím:HER2, P53, FAS, FASL, COX2, PGE2S, EGFR expression in breast cancer and in normal peritumoral breast tissue : potential novel risk biomarkers / Edit Nádasi, János Sándor, Marcella Mottolese, AnnaMaria Cianciulli, Pier Giorgio Natali, István Ember
Dátum:2004
Megjegyzések:We analyzed, by using specific antibodies, HER2, p53, Fas and Fas ligand (FasL), expression in 72 breast carcinomas, the corresponding autologous peritumoral tissues (PTT) sampled at 1, 2 and 3 cm from the tumor itself and in 44 benign mammary lesions. Ten breast carcinomas and their autologous 1-cm PTT samples were also analyzed by fluorescent in situ hybridization (FISH) to determine if HER2 gene amplification can be demonstrated in the background of cytoplasmic immunohistochemical HER2 staining. A further 186 stage I-II primary BC and 95 autologous lymph node metastases were analyzed immunohistochemically for cyclooxygenase-2 (COX2), hormone receptors, p53, HER2, Ki67, Fas, FasL and epidermal growth factor receptor (EGFR) expression, to determine their effects on the prognosis of breast cancer patients receiving chemotherapy. The results obtained suggest that HER2 gene amplification often underlies cytoplasmic HER2 staining when analyzed immunohistochemically. Furthermore, breast carcinomas and the closest adjacent uninvolved parenchyma shared an up-regulated FasL phenotype, which is lost in PTT farther from the tumor. Therefore, among the biological parameters investigated, HER2 and FasL expressions seem to represent biomarkers of breast tumorigenesis easily applicable to fine-needle aspirates and potentially useful to detect patients at high risk of breast carcinoma. Moreover, in high-risk breast cancer patients, the immunohistochemical evaluation of COX2, together with PGE2S, p53, Ki67, HER2, Fas and FasL, may be of clinical value in determining 5-year disease-free survival and overall survival for the patient.
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
Breast cancer
Megjelenés:Anticancer Research. - 24 : 5D Suppl (2004), p. 3574. -
További szerzők:Sándor János (1966-) (orvos-epidemiológus) Mottolese, Marcella Cianciulli, AnnaMaria Natali, Pier Giorgio Ember István
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM051574
035-os BibID:PMID:17352244
Első szerző:Nádasi Edit
Cím:Prognostic factors in Hungarian breast cancer patients / Edit Nádasi, Béla Anga, János Sándor, Judit Megyesi, Dezső Kelemen, Marcella Mottolese, Pier Giorgio Natali, Géza Hegedűs, István Arany, István Ember
Dátum:2007
Megjegyzések:Breast cancer is the most common cancer among women, with variable outcomes, justifying a continuous search for new parameters to predict accurate prognosis and indicate suitable adjuvant therapy for patients. MATERIALS AND METHODS: Fourty-four stage I-III breast cancer specimens were investigated immunohistochemically for the expression of cyclooxygenase-2 enzyme (COX-2), hormone receptors, tumor suppressor gene p53, oncogene HER2 and proliferation marker Ki-67. Additionally, twelve specimens were also investigated for the presence of the phosphorylated extracellular signal-regulated kinase (pERK). RESULTS: It was demonstrated that expressions of biological markers were related to each other (ER to p53 and Ki-67, COX-2 to ER, PgR, Ki-67 and p53, Ki-67 to p53 and PgR, p53 to PgR). CONCLUSION: Our data indicate that concomitant immunohistochemical evaluation of cyclooxygenase-2, hormone receptors, p53 and Ki-67 may be of clinical value in determining an accurate prognosis.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
breast cancer
immunohistochemistry
prognostic factors
activated extracellular signal-regulated kinase
odds ratio
Megjelenés:Anticancer Research. - 27 : 1A (2007), p. 279-282. -
További szerzők:Anga Béla Sándor János (1966-) (orvos-epidemiológus) Megyesi Judit Kelemen Dezső Mottolese, Marcella Natali, Pier Giorgio Hegedűs Géza Arany István Ember István
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM105442
Első szerző:Orsós Zsuzsa
Cím:Allelic polymorphisms of metabolizing enzymes in a Hungarian roma population / Zsuzsa Orsós, Judit Béres, János Sándor, István Ember, István Kiss
Dátum:2004
ISSN:0250-7005 1791-7530
Megjegyzések:The Roma population is the largest ethnic minority in Hungary. Their mortality structure differs from the national average. This is partly caused by life-style, environmental and social factors, but genetic factors may also be responsible. Concerning cancer morbidity and mortality, such genetic factors can be polymorphisms of certain metabolizing enzymes, which (based on literature data and on our previous studies) may have an influence on susceptibility to cancer. In the present study, we investigated the allelic polymorphisms of N-acetyltransferase 2 (NAT2), a glutathione-S-transferase M1 (GSTM1), glutathione-S transferase T1 (GSTT1) and cytochrome P450 1A1 (CYP 1A1) metabolizing enzymes in a large group of the Hungarian Romas. The allelic freqencies were compared to the data for the non Roma population. Sample collection was performed in the framework of Roma Project (195 blood samples), genotyping was made from peripheral leukocytes, with PCR based methods (NAT2: rapid and slow acetylators, GST M1 and T1: 0 and + genotypes, CYP 1A1: Ile/Val polymorphism). Our results demonstrated a difference between the allelic distributions of Roma and non Roma populations. Allelic frequencies of GSTM1 (OR: 2.08, 95% CI: 1.45-2.99) and NAT2 (OR: 1.42, 95% CI: 1.00-2.00) were significantly different, while in the case of GSTT1 and CYP 1A1, there was no statistically significant difference. Since both GSTM1 and NAT polymorphisms might have an influence on susceptibility to certain cancers (e.g. colorectal, bladder and lung cancer), the differences found in the allelic distributions may contribute to the mortality differences between the Hungarian Roma and non Roma populations. This hypothesis, however, must be confirmed, e.g. by studying allelic polymorphisms among cancer patients from the Roma population.
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
ALLELIC POLYMORPHISMS
Megjelenés:Anticancer Research. - 24 : 5D Suppl (2004), p. 3587. -
További szerzők:Béres Judit Sándor János (1966-) (orvos-epidemiológus) Ember István Kiss István
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM051576
035-os BibID:PMID:10928094
Első szerző:Pajkos Gábor
Cím:The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer / Gábor Pajkos, István Kiss, János Sándor, István Ember, Péter Kisházi
Dátum:2000
Megjegyzések:The predictive and prognostic value of the c-K-ras mutation is still unequivocal despite extensive and intensive studies. Investigation of the occurrence of mutations in 88 colorectal cancer patients' specimens using the polymerase chain reaction (PCR) is reported: age: 61.9 years (27-80), gender: 48 male, 42 female, Dukes' stages: 43 at B, 35 at C, 10 at D, primary of tumour: 52 colon, 36 rectal adenocarcinoma. Mutation of one of the three ras-codons was detectable in the 54 cases, more frequently at the Dukes' stage C (p < 0.05). The ras-mutation correlated to a more elevated death-rate in the Dukes' B and C stages (p < 0.01). Mean survival time and time to progression were significantly longer at the Dukes' stage B if mutation was not detected (p < 0.01). The genetic alteration occurred significantly more frequently at tumours of the right-side colon, than the left side (p < 0.02) or rectum (p < 0.05). However, in the age group of 41-50 years, it was more significantly identified in the cases of rectal cancer (p < 0.01). At the age of 51-60 years mutations were detected in men at a higher rate (p < 0.05). The mutation of the codon 13 appeared more frequently in the cases of local recurrences (p < 0.05). The occurrence of the ras-oncogene is a sign of an extremely malignant potential of tumour. This fact manifested itself in the time to progression and mean survival time of patients at the same clinical or pathological stage. The higher frequency of genetic alterations at the proximal colon may be the reason for more unfavourable prognosis of the disease localised to this site. Reconstructing the molecular events, the presence of the ras mutation proved to be an important element for prognosis of the disease and should be a basis of potentially individualised therapeutic intervention.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
Coltlrectal cancer
K-ras oncogene
MASA-
PCR-method
Megjelenés:Anticancer Research. - 20 : 3A (2000), p. l695-1702. -
További szerzők:Kiss István (Pécs) Sándor János (1966-) (orvos-epidemiológus) Ember István Kisházi Péter
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1